Morgan Stanley’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-3
| Closed | – | – | 7727 |
|
|
2020
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 7298 |
|
|
2020
Q3 | $0 | Buy |
3
+2
| +200% | +$9 | ﹤0.01% | 6989 |
|
|
2020
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 6910 |
|
|
2020
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 6922 |
|
|
2019
Q4 | $0 | Sell |
1
-113
| -99% | -$731 | ﹤0.01% | 6885 |
|
|
2019
Q3 | $1K | Buy |
114
+1
| +0.9% | +$8 | ﹤0.01% | 6605 |
|
|
2019
Q2 | $1K | Buy |
113
+1
| +0.9% | +$7 | ﹤0.01% | 6612 |
|
|
2019
Q1 | $1K | Hold |
112
| – | – | ﹤0.01% | 6564 |
|
|
2018
Q4 | $1K | Buy |
112
+5
| +5% | +$60 | ﹤0.01% | 6555 |
|
|
2018
Q3 | $2K | Buy |
107
+62
| +138% | +$747 | ﹤0.01% | 6601 |
|
|
2018
Q2 | $0 | Sell |
45
-17
| -27% | -$151 | ﹤0.01% | 6824 |
|
|
2018
Q1 | $1K | Buy |
62
+22
| +55% | +$226 | ﹤0.01% | 6572 |
|
|
2017
Q4 | $0 | Sell |
40
-60
| -60% | -$725 | ﹤0.01% | 6736 |
|
|
2017
Q3 | $2K | Sell |
100
-716
| -88% | -$8.45K | ﹤0.01% | 6417 |
|
|
2017
Q2 | $7K | Sell |
816
-3,126
| -79% | -$61.2K | ﹤0.01% | 6311 |
|
|
2017
Q1 | $104K | Buy |
+3,942
| New | +$141K | ﹤0.01% | 5587 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6609 |
|
|
2016
Q3 | – | Sell |
-1
| Closed | -$28 | – | 6607 |
|
|
2016
Q2 | $0 | Buy |
+1
| New | +$38 | ﹤0.01% | 6757 |
|
|
2014
Q3 | – | Sell |
-12
| Closed | -$5K | – | 6723 |
|
|
2014
Q2 | $5K | Buy |
12
+1
| +9% | +$461 | ﹤0.01% | 6294 |
|
|
2014
Q1 | $5K | Hold |
11
| – | – | ﹤0.01% | 6253 |
|
|
2013
Q4 | $5K | Buy |
+11
| New | +$5.38K | ﹤0.01% | 6161 |
|
|
2013
Q3 | – | Sell |
-174
| Closed | -$82K | – | 5428 |
|
|
2013
Q2 | $82K | Buy |
+174
| New | +$78.9K | ﹤0.01% | 5119 |
|
Other funds holding IDXG
Morgan Stanley's IDXG Position: Q1 2021 in Review
Morgan Stanley sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2021, closing a stake of 3 shares.
Morgan Stanley first reported a position in IDXG in Q2 2013 and held it in 21 quarters. The position peaked at $104K in Q1 2017. 3 funds tracked by Wall St. Rank hold IDXG as of Q1 2021.
- Morgan Stanley reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
- Morgan Stanley sold 3 Interpace Biosciences, Inc. Common Stock shares in Q1 2021.
- Morgan Stanley first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 21 quarters.
- Morgan Stanley's Interpace Biosciences, Inc. Common Stock position peaked at $104K in Q1 2017.
- 3 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2021.
Based on Morgan Stanley's 13F filing for Q1 2021, filed 17 May 2021.